Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 10 (October)

1. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
   Br J Cancer, 99(7): 1103-13. [Abstract] [Full-text]
2. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
   Carcinogenesis, 29(10): 1893-900. [Abstract] [Full-text]
3. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
   Carcinogenesis, 29(10): 1963-6. [Abstract] [Full-text]
4. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.
   J Clin Oncol, 26(29): 4820-7. [Abstract] [Full-text]
5. Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors.
   Pathol Int, 58(11): 681-6. [Abstract] [Full-text]
6. Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene.
   Cancer Lett, 271(2): 205-14. [Abstract] [Full-text]
7. C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.
   Br J Cancer, 99(8): 1269-75. [Abstract] [Full-text]
8. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
   Am J Clin Pathol, 130(5): 771-9. [Abstract] [Full-text]
9. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
   Gynecol Oncol, 111(1): 89-94. [Abstract] [Full-text]
10. Proteomic studies of early-stage and advanced ovarian cancer patients.
    Gynecol Oncol, 111(1): 111-9. [Abstract] [Full-text]
11. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Gynecol Oncol, 111(1): 95-101. [Abstract] [Full-text]
12. What women with ovarian cancer think and know about genetic testing.
    Gynecol Oncol, 111(1): 132-6. [Abstract] [Full-text]
13. SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells.
    Gynecol Oncol, 111(1): 125-31. [Abstract] [Full-text]
14. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Gynecol Oncol, 111(1): 106-10. [Abstract] [Full-text]
15. Adjuvant radiation for early stage endometrial cancer with lymphovascular invasion.
    Gynecol Oncol, 111(1): 49-54. [Abstract] [Full-text]
16. Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer.
    BMC Cancer, 8: 292. [Abstract] [Full-text]
17. Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
    Ann Surg, 248(5): 836-41. [Abstract] [Full-text]
18. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
    Cancer Immunol Immunother, 58(1): 15-23. [Abstract] [Full-text]
19. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
    Am J Surg Pathol, 32(11): 1667-74. [Abstract] [Full-text]
20. Comparison of STAT3 with HIF-1alpha, Ob and ObR expressions in human endometrioid adenocarcinomas.
    Tissue Cell, 40(6): 405-10. [Abstract] [Full-text]

© 2004-2010 Ovarian Cancer Research Today. All Rights Reserved.